A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area

Geoffrey S Dow, William F McCarthy, Mark Reid, Bryan Smith, Douglas Tang, G Dennis Shanks, Geoffrey S Dow, William F McCarthy, Mark Reid, Bryan Smith, Douglas Tang, G Dennis Shanks

Abstract

Background: In 2000/2001, the Australian Defense Forces (ADF), in collaboration with SmithKline Beecham and the United States Army, conducted a field trial to evaluate the safety, tolerability and efficacy of tafenoquine and mefloquine/primaquine for the prophylaxis of malaria amongst non-immune Australian soldiers deployed to East Timor (now called Timor Leste) for peacekeeping operations. The lack of a concurrent placebo control arm prevented an internal estimate of the malaria attack rate and so the protective efficacy of the study regimens was not determined at the time.

Methods: In a retrospective analysis of the trial results, the all species malaria attack rate was estimated for the prophylactic phase of the study which was defined as the period between administration of the first prophylactic dose and the first dose of post-deployment medication. First, the Plasmodium vivax attack rate was estimated during the prophylactic phase of the deployment by adjusting the observed P. vivax relapse rate during post-deployment to account for the known anti-relapse efficacies (or effectiveness) of the study medications (determined from prior studies). The all species malaria attack rate (P. vivax and Plasmodium falciparum) was then determined by adjusting the P. vivax attack rate based on the ratio of P. falciparum to P. vivax observed during prior ADF deployments to Timor Leste. This estimated all species malaria attack rate was then used as the 'constant estimated attack rate' in the calculation of the protective efficacy of tafenoquine and mefloquine during the prophylactic phase of the deployment.

Results: The estimated attack rate during the prophylactic phase of the study was determined to be 7.88%. The protective efficacies of tafenoquine and mefloquine, with corresponding 95% confidence intervals (95% CI), were determined to be 100% (93%-100%) and 100% (79%-100%) respectively.

Conclusions: The protective efficacy of tafenoquine (200 mg per day for three days, followed by weekly 200 mg maintenance doses) is similar to that of the weekly standard of care (mefloquine, 250 mg).

References

    1. Charles BG, Miller AL, Nasveld PE, Reid MG, Harris IE, Edstein MD. Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects. Antmicrob Agents Chemother. 2007;51:2709–2715. doi: 10.1128/AAC.01183-06.
    1. Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkurmah F, Ritchie TL, Franke ED, Binka FN, Horton J, Hoffman SL. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis. 2003;36:541–549. doi: 10.1086/367542.
    1. Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, Horton J, Brueckner R. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis. 2001;33:1968–1974. doi: 10.1086/324081.
    1. Walsh DS, Eamsila C, Sasiprapha T, Sangkharomya S, Khaewsathien P, Supakalin P, Tang DB, Jarasrumsichol P, Cherdchu C, Edstein MD, Rieckmann KH, Brewer TG. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multi-drug resistant P. falciparum malaria. J Infect Dis. 2004;190:1456–1463. doi: 10.1086/424468.
    1. Dow GD, Magill AJ, Ohrt C. Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki. Ther Clin Risk Manag. 2008;4:803–819.
    1. Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, Leggat PA, Pickford P, Kerr C, Ohrt C, Prescott W. Tafenoquine Study Team. Randomized, double-blind study of the safety, tolerability and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in non-immune subjects. Antimicrob Agents Chemother. 2010;54:792–798. doi: 10.1128/AAC.00354-09.
    1. Bragonier R, Reyburn H, Nasveld P, Edstein M, Auliffe A. Rainy-season malaria prevalence in Bobonaro district, East Timor. Ann Trop Med Parasitol. 2002;96:739–743. doi: 10.1179/000349802125008143.
    1. Kolaczinski J, Webster J. Malaria control in complex emergencies: the example of East Timor. Trop Med Int Health. 2003;8:48–55. doi: 10.1046/j.1365-3156.2003.00969.x.
    1. Martins JA, Zwi AB, Martins N, Kelly PM. Malaria control in Timor-Leste during a period of political instability: what lessons can be learned? Conflict and Health. 2009;3:11. doi: 10.1186/1752-1505-3-11.
    1. WHO. “Weekly International Health Bulletin for East Timor, 1999 Week 44 – 2001 Week 39. Geneva: WHO; 1999.
    1. FDA. Draft Guidance for Industry – Malaria: Developing drugs and non-vaccine biological products for treatment and prophylaxis. Washington DC: United States Department of Health and Human Services; 2007.
    1. Kitchener SJ, Auliff AM, Rieckmann KH. Malaria in the Australian Defence Force during and after participation in the International Force in East Timor (INTERFET) Med J Aust. 2000;173:583–585.
    1. Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, Roskell NS, Chulay JD. Malarone International Study Team. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in non-immune travelers: results from a randomized, double-blind study. Clin Infect Dis. 2001;33:1015–1021. doi: 10.1086/322694.
    1. Moon JE, Deye GA, Miller L, Fracisco S, Miller RS, Tosh D, Cummings JF, Ohrt C, Magill AJ. Plasmodium falciparum infection during suppressive prophylaxis with mefloquine does not induce an antibody response to merozoite surface protein-1(42) Am J Trop Med Hyg. 2011;84:825–829. doi: 10.4269/ajtmh.2011.10-0699.
    1. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, Price RN. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012;11:280. doi: 10.1186/1475-2875-11-280.
    1. Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure of Plasmodium vivax malaria in the Southwest Pacific. Trans R Soc Trop Med Hyg. 2008;102:1095–1101. doi: 10.1016/j.trstmh.2008.04.024.
    1. Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, Kyle D, Milhous W, Kenworthy D, Miller A, Veazey J, Ohrt C. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta) Malar J. 2011;20:212.
    1. Peters W, Robinson BL, Milhous WK. The chemotherapy of rodent malaria, LI. Studies on a new 8-aminoquinoline, WR 238,605. Ann Trop Med Parasitol. 1993;87:547–552.
    1. Joy RJT. Malaria in American troops in the south and Southwest pacific in world War II. Medical History. 1999;43:192–207. doi: 10.1017/S002572730006508X.
    1. Australian Government Department of Health. Introduction to the national notifiable disease surveillance system. .
    1. Australian Government National Health and Medical Research Council. National statement on ethical conduct in human research (2007) – updated December 2013. .
    1. Baird JK, Basri H, Subianto B, Fryauff DJ, McElroy PD, Lekasana B, Ritchie TL, Masbar S, Wignall FS, Hoffman SL. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis. 1995;171:1678–1682. doi: 10.1093/infdis/171.6.1678.
    1. Leslie T, Mayan I, Mohammed B, Erasmus P, Kolaczinski J, Whitby CJ, Rowland M. A randomized trial of an eight week, once-weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS One. 2008;3:e2861. doi: 10.1371/journal.pone.0002861.
    1. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC. Long-term malaria prophylaxis with weekly mefloquine. Lancet. 1993;341:848–51. doi: 10.1016/0140-6736(93)93058-9.
    1. Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P, Phillips-Howard P, Nevill C, Sturchler D. Mefloquine compared with other malaria chemoprophylactic regimens in tourist visiting east Africa. Lancet. 1993;341:1299–303. doi: 10.1016/0140-6736(93)90814-W.
    1. Ohrt C, Purnomo, Sutamihardja MA, Tang D, Kain KC. Impact of microscopy error on estimates of protective efficacy in malaria-prevention trials. J Infect Dis. 2002;186:540–546. doi: 10.1086/341938.
    1. Edstein MD, Kocisko DA, Eamsila C, Charles BG, Rieckmann KH. Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers receiving monthly prophylaxis. Clin Infect Dis. 2003;37:1654–1658. doi: 10.1086/379718.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren